Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs ProShares UltraPro S&P500 (UPRO) Price & Performance

Abbott LaboratoriesTrade
ProShares UltraPro S&P500Trade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs ProShares UltraPro S&P500 — how do they compare? Abbott Laboratories trades at $111.04 (market cap $187.95B), while ProShares UltraPro S&P500 trades at $154.85. The key difference: Abbott Laboratories pays a 2.32% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.

ABTUPRO
Market Cap
$187.95B
Sector
HealthLeveraged / Inverse
52-Week High
$136.62$155.10
52-Week Low
$82.57$89.29
Enterprise Value
$214.96B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

ProShares UltraPro S&P500

UPRO, a leveraged ETF tracking the S&P 500, trades at $154.9 with a slight 0.06% decline. Technical indicators show a bullish trend with strong moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. Support lies at $152, with resistance at $155. Recent news highlights institutional buying and S&P 500 volatility amid inflation data and AI-driven earnings optimism.

The outlook for UPRO hinges on S&P 500 momentum, with bullish technicals but overbought risks. Upside potential exists if the index breaks resistance, but high leverage amplifies losses during pullbacks. Key risks include market volatility, inflation concerns, and stretched valuations. Investors should weigh the ETF's leveraged structure against broader market trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About ProShares UltraPro S&P500

UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.

Read more on UPRO